Analysis of Fas ligand gene mutation in patients with systemic lupus erythematosus

Takeshi Kojima, Takahiko Horiuchi, Hiroaki Nishizaka, Takuya Sawabe, Masanori Higuchi, Shin Ichi Harashima, Shigeru Yoshizawa, Hiroshi Tsukamoto, Kohei Nagasawa, Yoshiyuki Niho

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective. To investigate the possible association of a Fas ligand (FasL) gene mutation(s) or polymorphism(s) with systemic lupus erythematosus (SLE). Methods. For amplification of the introns of the FasL gene, long polymerase chain reaction (PCR) using exon-based primers was utilized, followed by partial sequencing to construct exon-specific oligonucleotide primers for the analyses of FasL genomic DNA in SLE patients. Structural defects were studied by use of a composite analysis of reverse transcriptase- PCR/single-strand conformational polymorphism (SSCP) analysis of messenger RNA (mRNA) transcripts of the FasL gene in 35 SLE patients and PCR/SSCP analysis of FasL genomic DNA in 143 SLE patients. Results. The sizes of the introns were ~0.6 kb for intron 1, 4.3 kb for intron 2, and 1.3 kb for intron 3. By SSCP analysis, we did not identify any mutations or polymorphisms in the FasL mRNA transcripts or in any of the 4 exons or areas of the introns adjacent to the exons. Conclusion. Using the same methods used in the present studies (PCR/SSCP), one group of investigators identified a structural defect of the FasL molecule in 1 of 75 SLE patients evaluated. Among the 143 SLE patients in the present study, however, we did not identify any mutations or polymorphisms of the FasL gene. Our results suggest that a FasL defect is not the major contributing factor in the pathogenesis of SLE.

Original languageEnglish
Pages (from-to)135-139
Number of pages5
JournalArthritis and rheumatism
Volume43
Issue number1
DOIs
Publication statusPublished - Jan 1 2000

Fingerprint

Fas Ligand Protein
Systemic Lupus Erythematosus
Introns
Mutation
Genes
Exons
Polymerase Chain Reaction
Messenger RNA
DNA Primers
DNA
Reverse Transcriptase Polymerase Chain Reaction
Research Personnel

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

Analysis of Fas ligand gene mutation in patients with systemic lupus erythematosus. / Kojima, Takeshi; Horiuchi, Takahiko; Nishizaka, Hiroaki; Sawabe, Takuya; Higuchi, Masanori; Harashima, Shin Ichi; Yoshizawa, Shigeru; Tsukamoto, Hiroshi; Nagasawa, Kohei; Niho, Yoshiyuki.

In: Arthritis and rheumatism, Vol. 43, No. 1, 01.01.2000, p. 135-139.

Research output: Contribution to journalArticle

Kojima, T, Horiuchi, T, Nishizaka, H, Sawabe, T, Higuchi, M, Harashima, SI, Yoshizawa, S, Tsukamoto, H, Nagasawa, K & Niho, Y 2000, 'Analysis of Fas ligand gene mutation in patients with systemic lupus erythematosus', Arthritis and rheumatism, vol. 43, no. 1, pp. 135-139. https://doi.org/10.1002/1529-0131(200001)43:1<135::AID-ANR17>3.0.CO;2-Q
Kojima, Takeshi ; Horiuchi, Takahiko ; Nishizaka, Hiroaki ; Sawabe, Takuya ; Higuchi, Masanori ; Harashima, Shin Ichi ; Yoshizawa, Shigeru ; Tsukamoto, Hiroshi ; Nagasawa, Kohei ; Niho, Yoshiyuki. / Analysis of Fas ligand gene mutation in patients with systemic lupus erythematosus. In: Arthritis and rheumatism. 2000 ; Vol. 43, No. 1. pp. 135-139.
@article{ea05094e415d4f2198cffe995b8a2db3,
title = "Analysis of Fas ligand gene mutation in patients with systemic lupus erythematosus",
abstract = "Objective. To investigate the possible association of a Fas ligand (FasL) gene mutation(s) or polymorphism(s) with systemic lupus erythematosus (SLE). Methods. For amplification of the introns of the FasL gene, long polymerase chain reaction (PCR) using exon-based primers was utilized, followed by partial sequencing to construct exon-specific oligonucleotide primers for the analyses of FasL genomic DNA in SLE patients. Structural defects were studied by use of a composite analysis of reverse transcriptase- PCR/single-strand conformational polymorphism (SSCP) analysis of messenger RNA (mRNA) transcripts of the FasL gene in 35 SLE patients and PCR/SSCP analysis of FasL genomic DNA in 143 SLE patients. Results. The sizes of the introns were ~0.6 kb for intron 1, 4.3 kb for intron 2, and 1.3 kb for intron 3. By SSCP analysis, we did not identify any mutations or polymorphisms in the FasL mRNA transcripts or in any of the 4 exons or areas of the introns adjacent to the exons. Conclusion. Using the same methods used in the present studies (PCR/SSCP), one group of investigators identified a structural defect of the FasL molecule in 1 of 75 SLE patients evaluated. Among the 143 SLE patients in the present study, however, we did not identify any mutations or polymorphisms of the FasL gene. Our results suggest that a FasL defect is not the major contributing factor in the pathogenesis of SLE.",
author = "Takeshi Kojima and Takahiko Horiuchi and Hiroaki Nishizaka and Takuya Sawabe and Masanori Higuchi and Harashima, {Shin Ichi} and Shigeru Yoshizawa and Hiroshi Tsukamoto and Kohei Nagasawa and Yoshiyuki Niho",
year = "2000",
month = "1",
day = "1",
doi = "10.1002/1529-0131(200001)43:1<135::AID-ANR17>3.0.CO;2-Q",
language = "English",
volume = "43",
pages = "135--139",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Analysis of Fas ligand gene mutation in patients with systemic lupus erythematosus

AU - Kojima, Takeshi

AU - Horiuchi, Takahiko

AU - Nishizaka, Hiroaki

AU - Sawabe, Takuya

AU - Higuchi, Masanori

AU - Harashima, Shin Ichi

AU - Yoshizawa, Shigeru

AU - Tsukamoto, Hiroshi

AU - Nagasawa, Kohei

AU - Niho, Yoshiyuki

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Objective. To investigate the possible association of a Fas ligand (FasL) gene mutation(s) or polymorphism(s) with systemic lupus erythematosus (SLE). Methods. For amplification of the introns of the FasL gene, long polymerase chain reaction (PCR) using exon-based primers was utilized, followed by partial sequencing to construct exon-specific oligonucleotide primers for the analyses of FasL genomic DNA in SLE patients. Structural defects were studied by use of a composite analysis of reverse transcriptase- PCR/single-strand conformational polymorphism (SSCP) analysis of messenger RNA (mRNA) transcripts of the FasL gene in 35 SLE patients and PCR/SSCP analysis of FasL genomic DNA in 143 SLE patients. Results. The sizes of the introns were ~0.6 kb for intron 1, 4.3 kb for intron 2, and 1.3 kb for intron 3. By SSCP analysis, we did not identify any mutations or polymorphisms in the FasL mRNA transcripts or in any of the 4 exons or areas of the introns adjacent to the exons. Conclusion. Using the same methods used in the present studies (PCR/SSCP), one group of investigators identified a structural defect of the FasL molecule in 1 of 75 SLE patients evaluated. Among the 143 SLE patients in the present study, however, we did not identify any mutations or polymorphisms of the FasL gene. Our results suggest that a FasL defect is not the major contributing factor in the pathogenesis of SLE.

AB - Objective. To investigate the possible association of a Fas ligand (FasL) gene mutation(s) or polymorphism(s) with systemic lupus erythematosus (SLE). Methods. For amplification of the introns of the FasL gene, long polymerase chain reaction (PCR) using exon-based primers was utilized, followed by partial sequencing to construct exon-specific oligonucleotide primers for the analyses of FasL genomic DNA in SLE patients. Structural defects were studied by use of a composite analysis of reverse transcriptase- PCR/single-strand conformational polymorphism (SSCP) analysis of messenger RNA (mRNA) transcripts of the FasL gene in 35 SLE patients and PCR/SSCP analysis of FasL genomic DNA in 143 SLE patients. Results. The sizes of the introns were ~0.6 kb for intron 1, 4.3 kb for intron 2, and 1.3 kb for intron 3. By SSCP analysis, we did not identify any mutations or polymorphisms in the FasL mRNA transcripts or in any of the 4 exons or areas of the introns adjacent to the exons. Conclusion. Using the same methods used in the present studies (PCR/SSCP), one group of investigators identified a structural defect of the FasL molecule in 1 of 75 SLE patients evaluated. Among the 143 SLE patients in the present study, however, we did not identify any mutations or polymorphisms of the FasL gene. Our results suggest that a FasL defect is not the major contributing factor in the pathogenesis of SLE.

UR - http://www.scopus.com/inward/record.url?scp=0034046228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034046228&partnerID=8YFLogxK

U2 - 10.1002/1529-0131(200001)43:1<135::AID-ANR17>3.0.CO;2-Q

DO - 10.1002/1529-0131(200001)43:1<135::AID-ANR17>3.0.CO;2-Q

M3 - Article

VL - 43

SP - 135

EP - 139

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 1

ER -